Beta blocker Study Guide

📖 Core Concepts Beta‑adrenergic receptors: G‑protein‑coupled receptors (β1, β2, β3) that mediate catecholamine (epinephrine, norepinephrine) effects on heart, vasculature, bronchi, and metabolism. Beta blocker (β‑blocker): Competitive antagonist that blocks these receptors, blunting sympathetic stimulation. Selectivity Non‑selective – block β1 & β2 (e.g., propranolol). β1‑selective (cardioselective) – preferentially block β1 at therapeutic doses (e.g., metoprolol, atenolol, bisoprolol). Vasodilating/α‑blocking – add α1 antagonism or nitric‑oxide mediated vasodilation (e.g., carvedilol, labetalol, nebivolol). Intrinsic sympathomimetic activity (ISA) – partial agonism when endogenous catecholamines are low (e.g., acebutolol, pindolol). Lipophilicity vs. Hydrophilicity – determines CNS penetration; lipophilic agents (propranolol) cause central side‑effects, hydrophilic agents (atenolol) remain peripheral. 📌 Must Remember β1 blockade → ↓ heart rate, ↓ contractility, ↓ renin → ↓ cardiac output & BP. β2 blockade → ↓ bronchodilation & peripheral vasodilation → risk of bronchospasm. Key mortality‑improving β‑blockers in HFrEF: bisoprolol, carvedilol, sustained‑release metoprolol. Contraindications: severe asthma/COPD (non‑selective), severe bradycardia, AV block ≥ II° without pacemaker, acute decompensated HF (initial dose), untreated pheochromocytoma. Overdose antidote: IV glucagon (↑ cAMP independent of β‑receptors). CYP2D6 interactions: inhibitors (fluoxetine, paroxetine, duloxetine, bupropion) ↑ levels of propranolol, metoprolol, carvedilol → ↑ bradycardia/hypotension. 🔄 Key Processes Beta‑blockade of cardiac β1 receptors ↓ SA‑node firing → ↓ HR ↓ AV‑node conduction → slower ventricular rate (useful in AF) ↓ myocyte contractility → ↓ O₂ demand Renin‑angiotensin suppression β1 receptors on juxtaglomerular cells → ↓ renin → ↓ Ang II & aldosterone → ↓ Na⁺/water retention. Management of β‑blocker overdose Assess airway, breathing, circulation. Administer IV glucagon (initial 5‑10 mg bolus, then infusion 5 mg/h). Add high‑dose insulin + dextrose, saline, vasopressors as needed. Consider temporary pacing if refractory bradycardia. 🔍 Key Comparisons Non‑selective vs. β1‑selective Bronchospasm: high risk (non‑selective) vs. lower risk (β1‑selective, dose‑dependent). Renal excretion: often hydrophilic (atenolol) vs. variable. Lipophilic vs. Hydrophilic CNS effects: insomnia, nightmares (lipophilic) vs. minimal CNS (hydrophilic). Dialysis removal: hydrophilic agents are dialyzable; lipophilic are not. ISA vs. No ISA Resting HR: less reduction with ISA → useful in patients prone to bradycardia. Exercise tolerance: ISA may blunt exercise‑induced tachycardia less effectively. β‑blocker + α‑blockade (carvedilol/labetalol) vs. pure β‑blocker Vasodilation: present → lower peripheral resistance, useful in hypertension emergencies. Heart failure: carvedilol proven mortality benefit; pure β‑blockers also beneficial but lack α effect. ⚠️ Common Misunderstandings “All β‑blockers are contraindicated in asthma.” – Only non‑selective agents; cardioselective agents can be used cautiously at low doses. “β‑blockers always lower blood pressure in hypertension.” – They are less effective than first‑line agents; not first‑line for uncomplicated HTN. “ISA means the drug is useless for heart failure.” – ISA agents are not preferred for HFrEF because they do not provide full β‑blockade. “Propranolol’s CNS side‑effects are always harmful.” – They can be therapeutically exploited for performance anxiety. 🧠 Mental Models / Intuition “Beta‑blocker = ‘turn down the gas’ on the sympathetic engine.” – Visualize catecholamine → accelerator pedal; β‑blocker = foot off the pedal, reducing speed (HR) and power (contractility). Selectivity gradient – Think of a filter: non‑selective = wide‑mouth, β1‑selective = narrow‑mouth that lets β2 “pass” unless dose is high. Lipophilicity = “brain‑crossing passport.” – If the drug has a passport (high logP), it can enter the CNS; otherwise it stays in the periphery. 🚩 Exceptions & Edge Cases β1‑selectivity loss at high doses – Even atenolol can cause bronchospasm if given > 100 mg/day. Renal impairment – Hydrophilic agents (atenolol, sotalol) require dose reduction; lipophilic agents rely less on renal clearance. Thyrotoxicosis – β‑blockers (especially propranolol) also block peripheral conversion of T4 → T3; abrupt withdrawal can precipitate thyroid storm. Pregnancy – Generally safe, but non‑selective agents may affect fetal lung development; cardioselective preferred. 📍 When to Use Which Acute MI (within 24 h) → short‑acting, non‑selective (e.g., metoprolol IV) to blunt catecholamine surge. Chronic HFrEF → carvedilol, bisoprolol, or metoprolol CR (evidence‑based). Asthma or COPD → β1‑selective, lowest effective dose (e.g., bisoprolol). Performance anxiety → highly lipophilic propranolol (CNS penetration). Hypertensive emergency → labetalol (β + α blockade) IV. Diabetes with frequent hypoglycemia → avoid non‑selective agents; prefer cardioselective, monitor glucose. 👀 Patterns to Recognize “Beta‑blocker + bradycardia + hypotension” → think overdose or drug interaction (CYP2D6 inhibitor). “Bronchospasm after starting a new β‑blocker” → likely non‑selective or high dose of a cardioselective agent. “Fatigue + cold extremities” → classic β‑blocker side‑effect profile; differentiate from hypothyroidism. “Masking of hypoglycemia signs” → look for β‑blocker use in diabetic patients presenting with altered mental status. 🗂️ Exam Traps Distractor: “β‑blockers are first‑line for uncomplicated hypertension.” – Wrong; they are now second‑line. Distractor: “All β‑blockers have intrinsic sympathomimetic activity.” – Only a subset (acebutolol, pindolol). Distractor: “Carvedilol is purely a β‑blocker.” – Incorrect; it also blocks α1 and causes vasodilation. Distractor: “Glucagon works by stimulating β‑receptors.” – Misleading; glucagon raises cAMP downstream of β‑receptors, bypassing the blockade. Distractor: “Hydrophilic β‑blockers cannot cause CNS side‑effects.” – Mostly true, but high doses may still cross the BBB minimally; the key point is they have far less CNS activity than lipophilic agents. --- Use this guide for a rapid, confidence‑building review before your exam. Focus on the “must‑remember” facts, then drill the step‑by‑step mechanisms and decision rules. Good luck!